Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at a single treatment group of people receiving Acthar Gel, a medication being studied for use in uveitis — a condition involving inflammation inside the eye. Five people started the trial, two completed it, and three did not finish. The trial was measuring three main things related to eye inflammation: the degree of haziness in vision (using the Nussenblatt Grading Scale), the amount of protein floating in the fluid at the front of the eye (using the Laser Flare Scale), and the number of cells floating in that same fluid (using the Aqueous Cell Scale). A secondary measurement tracked eye pressure over a 24-hour period, known as diurnal intraocular pressure, recorded in millimetres of mercury (mmHg). The reported data shows that no numerical results were submitted to ClinicalTrials.gov for any of these outcome measures — not for the three primary inflammation scales, nor for the eye pressure measurement. Because the data was not reported, it is not possible to describe what scores or readings were recorded for participants during the trial. It is also worth noting that only two of the five participants completed the study, which was a very small number to begin with. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 4 Uveitis Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are male, or female and currently neither pregnant nor breastfeeding
- You have been diagnosed with severe non-infectious uveitis affecting the back of the eye (an inflammatory eye condition not caused by infection)
- Your eye condition is still active despite taking oral steroid tablets (such as prednisone) for at least 2 weeks, shown by at least one of the following: ongoing inflammatory lesions in the eye, significant inflammation in the front part of the eye, or significant cloudiness in the jelly-like substance inside the eye
- You are willing to gradually reduce your current steroid and immune-suppressing medicines to the lowest dose that still works, during the study
- If you are already taking medicines that affect the immune system for another condition, you have been on a stable dose for at least 2 weeks before the study begins
Who may not be able to join:
- You have certain other serious eye conditions, such as advanced diabetic eye disease, wet age-related macular degeneration, or structural problems in the eye that could cause damage unrelated to inflammation (confirm with trial site)
- You have Type 1 or Type 2 diabetes, tuberculosis, a history of hepatitis, stomach ulcers, a current active infection, or any other medical reason that would make the study treatment (Acthar Gel) unsafe for you
⚠️ Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Score on the Nussenblatt Grading Scale; Score on the Laser Flare Scale; Score on the Aqueous Cell Scale
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.